{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:53:23Z","timestamp":1789433603057,"version":"build-2803163510"},"reference-count":20,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[1998,4,1]],"date-time":"1998-04-01T00:00:00Z","timestamp":891388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1998,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Three lipid-based formulations of amphotericin B have been approved for use in various countries. The aim of this study was to compare Amphotec (ABCD; Sequus), AmBisome (AmBi; Nexstar), Abelcet (ABLC; The Liposome Co.), and conventional deoxycholate amphotericin B (Fungizone; Bristol Meyers Squibb) for the treatment of experimental systemic cryptococcosis. A model was established in 10-week-old female CD-1 mice by intravenous (i.v.) injection of 6.25 \u00d7 10\n            <jats:sup>5<\/jats:sup>\n            viable\n            <jats:italic>Cryptococcus neoformans<\/jats:italic>\n            yeast cells. Therapy began 4 days later, with i.v. administration three times per week for 2 weeks. Mice received either no treatment, 1 mg of Fungizone per kg of body weight, or 1, 5, or 10 mg of ABCD, AmBi, or ABLC per kg. Ninety percent of control mice died between days 15 and 34. All treatment regimens except ABLC at 1 mg\/kg prolonged survival compared with no treatment (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.01 to 0.001). All mice receiving 5 or 10 mg of ABCD or AmBi per kg and 90% of mice given 10 mg of ABLC per kg survived, whereas \u226450% of those given other treatment regimens survived. Fungizone was the least effective of the four formulations, with 5 or 10 mg of ABCD, AmBi, or ABLC per kg resulting in a significantly better outcome than Fungizone (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001). Among the three formulations, ABCD and AmBi were equally effective, both being better than ABLC at equal 5- or 10-mg\/kg doses (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001). Comparison of residual infectious burdens in various organs showed that each drug had some dose-responsive efficacy in three or more organs at escalating doses. In the brain, ABCD or AmBi at 5 or 10 mg\/kg or ABLC at 10 mg\/kg was more effective than Fungizone at 1 mg\/kg or no treatment, while ABCD or AmBi at 1 mg\/kg was as effective as ABLC at 10 mg\/kg. Similar results were obtained for the kidneys and lungs. In the spleen, ABCD at 10 mg\/kg cured all mice of infection and was superior to all other regimens. In the liver, AmBi at 5 mg\/kg was superior to an equal dose of ABCD or ABLC. Overall, the efficacies of ABCD and AmBi were equal to that of Fungizone at 1 mg\/kg and were about 10-fold better than that of ABLC, particularly in the brain; a comparative rank order of efficacies was ABCD \u2245 AmBi &gt; ABLC \u226b Fungizone. This is the first study that compared all four amphotericin B formulations.\n          <\/jats:p>","DOI":"10.1128\/aac.42.4.899","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:31:10Z","timestamp":1539045070000},"page":"899-902","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":86,"title":["Comparison of Fungizone, Amphotec, AmBisome, and Abelcet for Treatment of Systemic Murine Cryptococcosis"],"prefix":"10.1128","volume":"42","author":[{"given":"Karl V.","family":"Clemons","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->California Institute for Medical Research and Division of Infectious Diseases, Department of Medicine, Santa Clara Valley Medical Center, San Jose, California 95128, and Division of Infectious Disease and Geographic Medicine, Department of Medicine, Stanford University, Stanford, California 94305"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Stevens","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->California Institute for Medical Research and Division of Infectious Diseases, Department of Medicine, Santa Clara Valley Medical Center, San Jose, California 95128, and Division of Infectious Disease and Geographic Medicine, Department of Medicine, Stanford University, Stanford, California 94305"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Adler-Moore J. P. S. Chiang A. Satorius D. Guerra B. McAndrews E. J. McManus and R. T. Proffitt. 1991. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J. Antimicrob. Chemother. 28 (Suppl. B) : 63\u201371.","DOI":"10.1093\/jac\/28.suppl_B.63"},{"key":"e_1_3_2_3_2","first-page":"1","article-title":"Comparison of liposomal amphotericin B to amphotericin B for treatment of murine cryptococcal meningitis.","volume":"5","author":"Albert M. M.","year":"1995","unstructured":"Albert M. M. Stahl-Carroll T. L. Luther M. F. Graybill J. R. Comparison of liposomal amphotericin B to amphotericin B for treatment of murine cryptococcal meningitis. J. Mycol. Med. 5 1995 1 6","journal-title":"J. Mycol. Med."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.4.615"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.3.460"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.10.2144"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.9.1829"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/02681219380000491","article-title":"Comparison of a liposomal amphotericin formulation (AmBisome) and deoxycholate amphotericin (Fungizone) for the treatment of paracoccidioidomycosis.","volume":"31","author":"Clemons K. V.","year":"1993","unstructured":"Clemons K. V. Stevens D. A. Comparison of a liposomal amphotericin formulation (AmBisome) and deoxycholate amphotericin (Fungizone) for the treatment of paracoccidioidomycosis. J. Med. Vet. Mycol. 31 1993 387 394","journal-title":"J. Med. Vet. Mycol."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jac\/30.3.353","article-title":"Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis.","volume":"30","author":"Clemons K. V.","year":"1992","unstructured":"Clemons K. V. Stevens D. A. Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis. J. Antimicrob. Chemother. 30 1992 353 363","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/jac\/32.3.465","article-title":"Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis.","volume":"32","author":"Clemons K. V.","year":"1993","unstructured":"Clemons K. V. Stevens D. A. Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J. Antimicrob. Chemother. 32 1993 465 472","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00002030-199102000-00020","article-title":"Successful treatment of cryptococcal meningitis with liposomal amphotericin B after failure of treatment with fluconazole and conventional amphotericin B.","volume":"5","author":"Coker R.","year":"1991","unstructured":"Coker R. Tomlinson D. Harris J. Successful treatment of cryptococcal meningitis with liposomal amphotericin B after failure of treatment with fluconazole and conventional amphotericin B. AIDS 5 1991 231 232","journal-title":"AIDS"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.2.308"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0378-5173(91)90249-N","article-title":"Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs.","volume":"75","author":"Guo L. S. S.","year":"1991","unstructured":"Guo L. S. S. Fielding R. M. Lasic D. D. Hamilton R. L. Mufson D. Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs. Int. J. Pharm. 75 1991 45 54","journal-title":"Int. J. Pharm."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Hiemenz J. W. and T. J. Walsh. 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22 (Suppl. 2) : S133\u2013S144.","DOI":"10.1093\/clinids\/22.Supplement_2.S133"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.12.2656"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.16.6122"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"Lister J. 1996. Amphotericin B lipid complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Eur. J. Haematol. 56 (Suppl. 57) : 18\u201323.","DOI":"10.1111\/j.1600-0609.1996.tb01348.x"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/33.1.73","article-title":"Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis.","volume":"33","author":"Perfect J. R.","year":"1994","unstructured":"Perfect J. R. Wright K. A. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. J. Antimicrob. Chemother. 33 1994 73 81","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Proffitt R. T. A. Satorius S. Chiang L. Sullivan and J. P. Adler-Moore. 1991. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J. Antimicrob. Chemother. 28 (Suppl. B) : 49\u201361.","DOI":"10.1093\/jac\/28.suppl_B.49"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/clinids\/22.2.315","article-title":"Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patient with AIDS.","volume":"22","author":"Sharkey P. K.","year":"1996","unstructured":"Sharkey P. K. Graybill J. R. Johnson E. S. Hausrath S. G. Pollard R. B. Kolokathis A. Mildvan D. Fan-Havard P. Eng R. H. K. Patterson T. F. Pottage J. C. Jr. Simberkoff M. S. Wolf J. Meyer R. D. Gupta R. Lee L. W. Gordon D. S. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patient with AIDS. Clin. Infect. Dis. 22 1996 315 321","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_21_2","unstructured":"Sokal\n              R. R.\n              Rohlf\n              F. J.\n          Biometry\n          2nd ed.\n          1981\n          432\n          435\n          W. H. Freeman & Co.\n          San Francisco Calif"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.42.4.899","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.42.4.899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:48:13Z","timestamp":1645480093000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.42.4.899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1998,4]]}},"alternative-id":["10.1128\/AAC.42.4.899"],"URL":"https:\/\/doi.org\/10.1128\/aac.42.4.899","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,4]]},"assertion":[{"value":"1997-10-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-02-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}